|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
MGD |
|
|
|
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost as a function of prostate tumor androgen dependence.
|
16637073 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PTEN loss in Gleason score 6 biopsies identifies a subset of prostate tumors at increased risk of upgrading at radical prostatectomy.
|
24993522 |
2015 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PTEN loss stimulates prostate tumor progression by sustaining AKT activation.Nowak et al.(2019.<i>J.
|
31145683 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.
|
28319090 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
|
19396168 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Alterations in the PIK3CA and PTEN genes were assessed in 40 prostate tumors (radical prostatectomy samples).
|
19443396 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.
|
29335545 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Based on the identification of mutations in sporadic breast, brain and prostate tumours, we decided to examine the potential role of PTEN in sporadic malignant melanoma.
|
9764804 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Behavioral stress inhibited apoptosis and delayed prostate tumor involution both in phosphatase and tensin homolog-deficient (PTEN-deficient) prostate cancer xenografts treated with PI3K inhibitor and in prostate tumors of mice with prostate-restricted expression of c-MYC (Hi-Myc mice) subjected to androgen ablation therapy with bicalutamide.
|
23348742 |
2013 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
|
29295717 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
PosttranslationalModification
|
group |
LHGDN |
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
|
17606718 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.
|
22581815 |
2012 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis.
|
23248098 |
2013 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli.
|
12190124 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
|
12429629 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
|
22610119 |
2012 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Expression of mTOR signaling pathway markers in prostate cancer progression.
|
16652388 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
|
15897909 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Finally, higher levels of Akt activation are observed in human prostate cancer cell lines and xenografts lacking PTEN/MMAC1 expression when compared with PTEN/MMAC1-positive prostate tumors or normal prostate tissue.
|
9861013 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
|
9371490 |
1997 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, ADT combined with vaccination, specifically a DNA vaccine encoding the ligand-binding domain of the AR, led to improved antitumor responses as measured by tumor volumes and delays in the emergence of castrate-resistant prostate tumors in two murine prostate cancer models (Myc-CaP and prostate-specific PTEN-deficient mice).
|
29051161 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, we showed in preclinical models that BRG1 antagonist selectively inhibited the progression of PTEN-deficient prostate tumors.
|
30496141 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth.
|
25156255 |
2014 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Here, we provide evidence that PTEN loss in prostate tumours upregulates the expression of ADAM17, thereby activating NOTCH signalling.
|
27941799 |
2016 |